Little House Capital LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 10.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,991 shares of the medical research company’s stock after selling 230 shares during the period. Little House Capital LLC’s holdings in Thermo Fisher Scientific were worth $1,036,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the business. Legacy Investment Solutions LLC bought a new position in Thermo Fisher Scientific during the 3rd quarter valued at approximately $26,000. Peterson Financial Group Inc. bought a new position in shares of Thermo Fisher Scientific during the third quarter valued at $27,000. Barrett & Company Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. Missouri Trust & Investment Co purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $30,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.
Thermo Fisher Scientific Stock Down 0.0 %
Shares of TMO opened at $532.58 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $203.71 billion, a PE ratio of 32.22, a price-to-earnings-growth ratio of 3.18 and a beta of 0.77. The business’s 50 day moving average is $548.51 and its 200 day moving average is $570.52.
Thermo Fisher Scientific announced that its Board of Directors has initiated a stock repurchase plan on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its shares are undervalued.
Insider Buying and Selling at Thermo Fisher Scientific
In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock valued at $11,231,699 in the last 90 days. Insiders own 0.34% of the company’s stock.
Wall Street Analyst Weigh In
TMO has been the topic of a number of recent analyst reports. Bank of America cut their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Wells Fargo & Company upped their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Bernstein Bank boosted their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Finally, Citigroup raised their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $658.00.
Read Our Latest Report on Thermo Fisher Scientific
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
- Five stocks we like better than Thermo Fisher Scientific
- What is Forex and How Does it Work?
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Learn Technical Analysis Skills to Master the Stock Market
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.